Cour Pharmaceuticals Development Co., Inc.’s Post

Read to understand more about the drug therapies that COUR is working on!

💊 Expanded Access Programs, also known as "Compassionate Use", allow patients experimental alternatives to help treat their life-threatening conditions. 🔎 Discover what are the Conditions for Expanded Access to Treatment and the Challenges, Players and their Responsibilities that play significant roles in the process of expanded access to drugs. Find out more on 👉 https://lnkd.in/dhbun_eK By Juliana Priscila Vago #AcessToDrugs #ExpandedAcess #ArcadiaBlog #Arcadia

What's your strategy in keeping up with new drug modalities? The field of #drugdiscovery is advancing at an unprecedented pace, and both new and established modalities must be continuously reexamined to uncover novel combinations and more effective treatments: http://ms.spr.ly/6043Ypn1L

🚀 How do you stay ahead in the dynamic world of drug discovery? Keeping up with new drug modalities is key! 💡 Whether it's exploring innovative combinations or enhancing existing treatments, staying informed is crucial. Check out this insightful read: [http://ms.spr.ly/6043Ypn1L] #drugdiscovery #pharma #innovation

⭕ Learn More about The Most Famous Drug – #Allopurinol for #anti-gout Prescribed by Doctors and it’s Uses, Side Effects, Interactions, Warnings from #FADIC Blog: https://lnkd.in/d_nBAKkV

Liquid Active Drug calculation | Easy And Simple way | By. Mr. khan | Share and Subscribe My Channel.

PROMs are a valuable source of real-world data. They can help us to understand more about patient experiences with different treatment options and provide ongoing insight into the safety and efficacy of drugs. This paper explores the ways in which Sciensus is applying technology to collect ePROMs from the thousands of patients we support each year. To find out more, visit https://lnkd.in/evkhwrb3 #PROMs #CancerServices #realworlddata

The latest Rapid Action Drug Alerts and Response (RADAR) report, which presents changes on drug trends, harms and use of services in Scotland, has published today. The report seeks to inform immediate and short-term actions that reduce drug harms. View the report here: A digital dashboard has also been produced that presents the RADAR data in an easy to view format. View the dashboard: https://lnkd.in/eFNaUkV5

n-Lorem is different than standard drug development settings. Every risk/benefit decision that n-Lorem makes is in the context of the individual patient’s symptoms, status, and needs. While we cannot promise benefit, we can promise that we will do our very best in the creation of an optimal medicine. Stream part two of “How to Think About Risk”. https://lnkd.in/ehKhivXb